Bioenergetics in diabetic neuropathy: what we need to know by Hinder, Lucy M. et al.
Journal of the Peripheral Nervous System 17(Supplement):10–14 (2012)
REVIEW
Bioenergetics in diabetic neuropathy: what we need
to know
Lucy M. Hinder1, Andrea M. Vincent1, Charles F. Burant2, Subramaniam Pennathur2
and Eva L. Feldman1
1Department of Neurology and 2Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA
Abstract Progress in developing treatments for diabetic neuropathy is slowed by
our limited understanding of how disturbances in metabolic substrates – glucose and
fatty acids – produce nerve injury. In this review, we present the current oxidative
stress hypothesis and experimental data that support it. We identify weaknesses in our
understanding of diabetes-disordered metabolism in the neurovascular unit, that is, in critical
cell types of the microvascular endothelium, peripheral sensory neurons, and supporting
Schwann cells. Greater understanding of peripheral nervous system bioenergetics may
provide insight into new drug therapies or improvements in dietary interventions in diabetes
or even pre-diabetes.
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Diabetic neuropathy (DN) is a frequent and
severe complication of diabetes. It is more common
and persistent in patients with type 2 than type
1 diabetes (Young et al., 1993) and, over time,
DN affects approximately 60% of all patients with
the disease (Vincent and Feldman, 2004). DN is
characterized by progressive, length-dependent loss
of peripheral nerve axons in a stocking and glove
(distal to proximal) pattern (Said, 2007), resulting in
pain, decreased sensation, and eventually complete
loss of sensation. In the United States, DN is the
leading cause of diabetes-related hospital admissions
and non-traumatic amputations (Feldman et al., 2003;
Boulton et al., 2005; Edwards et al., 2008; Feldman,
2008). DN predominantly occurs in a distal symmetrical
pattern, with progressive skin denervation (reduced
intraepidermal nerve fiber density) (Said, 2007; Sullivan
et al., 2007) over the duration of diabetes (Shun
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et al., 2004), and a proximal-distal graded loss of
myelinated fiber density observed in the peripheral
nerves (Johnson et al., 1986).
The condition of diabetes mellitus is character-
ized by hyperglycemia. For decades, the persistent
or recurrent periods of hyperglycemia have been
thought to produce the microvascular complications
of diabetes including neuropathy, determined through
epidemiological studies (Chisholm, 1993; Epidemi-
ology of Diabetes Interventions and Complications,
1999). More recent studies also suggest a link between
dyslipidemia, a common risk factor for macro- and
micro-vascular disease, and DN (Vincent et al., 2009).
Hyperglycemia and dyslipidemia are predicted to pro-
duce gross aberrations in global energy balance and
metabolism that could lead to cellular injury and
neuropathy. Energy deficits are also predicted to
underlie the pathophysiological pattern of distal to
proximal injury through impaired ability to produce
energy at the extremities of long axons far from the
cell body. Despite the facts that energy metabolism
is generally well understood and that there has
been substantial research into bioenergetic failures
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that produce DN, there is little experimental data to
support the hypothesis for the fundamental cellular
mechanisms behind nerve injury. This lack of a clear
mechanism or mechanisms has prevented the devel-
opment of effective targeted treatments to prevent or
reverse DN. In this article, we consider the oxidative
stress theory of diabetes complications and available
bioenergetics data obtained in the peripheral nervous
system (PNS) to identify areas that may be fruitful for
developing greater understanding of DN.
An association between hyperglycemia-derived
production of reactive oxygen species (ROS) and
the development of DN is well-accepted (Brownlee,
2001; Tomlinson and Gardiner, 2008), with a primary
mechanism contributing to the onset and progression
of DN suggested to be related to hyperglycemia-
induced overproduction of superoxide (O•–2 ) by the
mitochondrial electron transport chain (Nishikawa
et al., 2000; Brownlee, 2001) (Fig. 1). In systemic
hyperglycemia, elevated glucose content in sciatic
nerve (SCN) (Thurston et al., 1995; Kishi et al., 1999;
Obrosova et al., 2005), and increased oxidative stress
in plasma, SCN and dorsal root ganglia (DRG) (Vincent
et al., 2004b), as well as in vitro hyperglycemia-induced
DRG neuron mitochondrial injury (Vincent et al., 2004a;
2005) all support the hypothesis that glycolytic
flux is increased in the diabetic PNS (Brownlee,
2001; Tomlinson and Gardiner, 2008), contributing to
mitochondrial ROS generation. Furthermore, enhanced
fatty acid oxidation and lipotoxicity are implicated in
the pathophysiology of type 2 diabetic cardiomyopathy
(van de Weijer et al., 2011) and nephropathy (Murea
et al., 2010). However, experimental evidence for
increased metabolic flux through glycolysis or beta-
oxidation in diabetic PNS is lacking. Brain glucose
utilization is more widely studied. Data suggest
that neurons continue to metabolize glucose during
hyperglycemia via non-glycolytic mechanisms, and that
there is a complex interplay between astroglia and
neurons to utilize metabolic substrates that is not well
understood (Izawa et al., 2009). Further understanding
of the utilization of energy substrates in specific nerve
cell types is critical.
The uptake and utilization of glucose are not
insulin dependent in peripheral neurons (Greene and
Winegrad, 1979). Glucose transporters (GLUT) are
required for facilitated glucose uptake: peripheral
neurons are dependent upon GLUT3 (Simpson et al.,
2008), and Schwann cells utilize both GLUT3 and
GLUT1 for facilitated glucose uptake (Magnani et al.,
1996). To our knowledge, the effects of diabetes on
this GLUT1 and GLUT3-mediated glucose transport
have not been investigated. Glucose accumulates in
SCN in alloxan-induced diabetes in rats at 26 weeks
Figure 1. Prevailing view that excessive glycolytic
metabolism is responsible for the generation of harmful reac-
tive oxygen species (ROS), mitochondrial injury, and diabetic
neuropathy. White boxes, experimental evidence derived
from neuronal tissue and cells; black boxes, associations
based on hypotheses derived from multiple, non-neuronal
tissue, and cell types.
(Thurston et al., 1995), and in streptozotocin (STZ)-
induced diabetic rats at 4 weeks (Kishi et al., 1999)
and 6 weeks (Obrosova et al., 2005), suggesting
no impairment of facilitated glucose transport into
the nerve in experimental diabetes. However, Kishi
et al. (1999) demonstrate that despite this elevated
SCN glucose content in STZ-diabetic rats after
1 month of diabetes, both nerve and DRG glucose
uptake are reduced compared with controls. Thus,
changes in glucose transporter expression and activity
warrant consideration and future investigation in the
detailed evaluation of peripheral nerve bioenergetics
in diabetes. In the face of poor glucose control, if
bioenergetics proves to be a key to neuron injury,
an ability to target specific GLUT may be one way to
protect peripheral neurons against an energy substrate
crisis.
In his unifying hypothesis, based primarily on
research in endothelial cells, Brownlee (2001) pro-
posed that ROS inhibition of glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) activity (Du et al.,
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2000) leads to accumulation of glyceraldehyde-3-
phosphate and upstream glycolytic metabolites, which
are then diverted into alternative pathways including
the advanced glycation end products pathway, PKC
pathway, hexosamine pathway, and polyol pathway
(Brownlee, 2001). Specifically, hyperglycemia is asso-
ciated with overproduction of tricarboxylic acid (TCA)
cycle-derived electron donors, subsequent increased
mitochondrial O•–2 production (Du et al., 2001) and O
•–
2 -
induced inhibition of GAPDH in cultured endothelial
cells (Du et al., 2000). Work by Thurston and colleagues
partially support this theory in peripheral nerves:
glucose-6-phosphate and fructose-1,6-bisphosphate
are elevated following 26 weeks of alloxan-induced
diabetes (Thurston et al., 1995). However, in the same
study, elevated nerve lactate and ATP lead to the con-
clusion that there is increased glycolysis and decreased
TCA cycle activity, although no TCA cycle intermedi-
ates were measured or quantified (Thurston et al.,
1995) to better support this conclusion.
Hexokinase directs glucose into the glycolytic
pathway under normoglycemic conditions, however,
there is a glucose concentration-dependent activation
of aldose reductase in nerve (Greene and Lattimer,
1983; Greene et al., 1984; 1987). Thus, activation
of the polyol pathway is a prominent metabolic
feature of diabetic rat peripheral nerve (Stevens et al.,
1994; Obrosova et al., 2005). Early in the course
of diabetes, this polyol flux promotes nicotinamide
adenine dinucleotide phosphate (NADPH) depletion,
decreased ATP production and neuron injury (Stevens
et al., 1994). Additionally, aldose reductase is localized
to Schwann cells in the peripheral nerve (Kern and
Engerman, 1982), and polyol pathway hyperactivity
is associated with diminished energy flux in diabetic
nerve (Greene and Lattimer, 1984; 1986). Hexokinase
saturation and maximal glycolytic flux is one of the
proposed mechanisms underlying the accumulation
of nerve glucose and its direction into the polyol
pathway in diabetes (Tomlinson and Gardiner, 2008);
however, there appear to be no data in the literature
on the degree of hexokinase activity in diabetic nerve.
Gardiner et al., (2007) observed complex effects of
STZ-induced diabetes on hexokinase I expression in
rat DRG and suggested that metabolic flux through
the glycolytic pathway is reduced in diabetes. Studies
on excised rat retinas (Ola et al., 2006) concluded
that glucose metabolism downstream of hexokinase
is not elevated by hyperglycemia or diabetes, but
that intermediates of alternative glucose metabolism,
such as those of the polyol pathway, are increased.
In clinical trials, inhibitors of aldose reductase have
generally failed to produce the desired results in
decreasing the progression of neuropathy, although
study data continue to suggest that improvements in
the inhibitors and trial design may ultimately produce
a therapeutic benefit (Tsai and Burnakis, 1993).
Work by Tretter and colleagues involving the
relationship between key enzymes of the TCA cycle
and oxidative stress suggests that in the absence
of metabolite flux from glycolysis to the TCA cycle,
ROS and subsequent further ROS generation by the
TCA cycle itself (Tretter and Adam-Vizi, 2005) may
contribute to mitochondrial dysfunction. Aconitase,
catalyzing the citrate to isocitrate reaction in the TCA
cycle, is inhibited by ROS, including O• –2 (Gardner
and Fridovich, 1992; Gardner et al., 1995) and H2O2
(Tretter and Adam-Vizi, 2005). When aconitase is
fully inhibited by H2O2 in nerve terminals, alpha-
ketoglutarate dehydrogenase (α-KGDH; catalyzing the
α-KG to succinyl-CoA reaction) remains functional and
a segment of the TCA cycle (α-KG to oxaloacetate)
is maintained by glutamate, which is converted to
α-KG via transamination (see Tretter and Adam-Vizi,
2005 for comprehensive explanation). ROS-mediated
inhibition of aconitase may cause this truncated TCA
cycle to come into effect in diabetic tissues (Fig. 2).
This truncated segment of the TCA cycle has been
suggested to function in the absence of glucose
(Yudkoff et al., 1994; Erecinska et al., 1996), and,
it could be inferred, when glucose is metabolized
by non-glycolytic pathways. Additionally, α-KGDH is
itself a source of ROS production, the level of which
increases when α-KG is utilized as a fuel source over
glucose in isolated brain synaptosomes (Tretter and
Adam-Vizi, 2004). Thus, in a state of oxidative stress
and/or decreased glycolysis, aconitase is completely
inhibited, and α-KGDH remains sufficiently active to
deliver electron donors to the electron transport chain,
but further contributes to the production of ROS
(Fig. 2). We have demonstrated loss of aconitase
activity in response to hyperglycemia in DRG neurons
in vitro (Vincent et al., 2005) but the consequences in
regards to ongoing energy metabolism in these cells
remain to be determined.
Thus, the theory that excessive glycolytic
metabolism is responsible for the generation of harm-
ful ROS, mitochondrial injury, and DN (Brownlee, 2001;
Tomlinson and Gardiner, 2008) is based on studies
that are disparate, incomplete, and performed across
multiple tissue and cell types. In addition, to our
knowledge, there are no studies that address the
interplay between glucose, fatty acids and periph-
eral nerve energy metabolism in diabetes, nor the
relationships between microvascular, Schwann cell,
and neuronal metabolism. With the development of
quantitative mass spectroscopy techniques, further
metabolite studies demand attention. An understand-
ing of diabetic metabolic abnormalities distinct to the
PNS may be crucial to developing effective treatments
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Figure 2. Proposed relationship between diabetes, ROS, and
the tricarboxylic acid (TCA) cycle. In a state of oxidative stress
and/or decreased glycolysis, aconitase is inhibited. α-KGDH
remains sufficiently active to permit truncated TCA cycling
and delivery of electron donors to the electron transport
chain, but further contributes to the production of ROS.
α-KGDH, alpha-ketoglutarate dehydrogenase; ROS, reactive
oxygen species.
for DN-related peripheral nerve disease. These data,
then, can more fully support the multiple mechanisms
that are proposed to be involved in cumulative neu-
ron and nerve injury in diabetes that include oxidative
stress, loss of neurotrophic support, insulin resis-
tance, myelin dysfunction, and inflammation (Vincent
et al., 2011).
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